CUBICIN ® (daptomycin for injection) for S. aureus Bacteremia Including Those With Known or Suspected Endocarditis David Mantus, Ph.D. Vice President, Regulatory Affairs Cubist Pharmaceuticals Adjunct Assistant Professor Massachusetts College of Pharmacy
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
CUBICIN® (daptomycin for injection) for S. aureus Bacteremia Including Those With Known or Suspected Endocarditis
David Mantus, Ph.D.
Vice President, Regulatory AffairsCubist Pharmaceuticals
Adjunct Assistant ProfessorMassachusetts College of Pharmacy
David Mantus, Ph.D.V.P. Regulatory AffairsCubist Pharmaceuticals
Helen Boucher, M.D.Assistant Professor of MedicineDir. Infectious Diseases Fellowship ProgramDiv. of Infectious Diseases and Geographic MedicineTufts University-NEMC
Jeff Alder, Ph.D.V.P. Drug Discovery & EvaluationCubistPharmaceuticals
Gloria Vigliani, M.D.V.P. Medical StrategyCubist Pharmaceuticals
G. Ralph Corey, M.D.Professor of Internal Medicine & Infectious DiseaseDuke University Medical Center
Daptomycin 6 mg/kg once daily: